These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21043539)

  • 1. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
    Willis M; Persson U; Zoellner Y; Gradl B
    Appl Health Econ Health Policy; 2010; 8(6):377-86. PubMed ID: 21043539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 3. [Continuous treatment with levodopa of Parkinson disease].
    Lundqvist C; Nystedt T; Reiertsen O; Grotli R; Beiske AG
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2638-40. PubMed ID: 16215609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
    Meppelink AM; Nyman R; van Laar T; Drent M; Prins T; Leenders KL
    Mov Disord; 2011 Feb; 26(2):331-4. PubMed ID: 20960486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knotting of Duodopa® duodenal infusion system.
    del-Hoyo-Francisco J; Bustamante-Balén M; Martínez-Torres I; Barrios-Barrios A; Satorres-Paniagua C; Pons-Beltrán V
    Rev Esp Enferm Dig; 2015 May; 107(5):323-4. PubMed ID: 25952811
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacoeconomic aspects of using levodopa/carbidopa intestinal gel in Parkinson's disease].
    Rudakova AV; Yakupov EZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(10):117-21. PubMed ID: 25614914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease.
    Pålhagen SE; Dizdar N; Hauge T; Holmberg B; Jansson R; Linder J; Nyholm D; Sydow O; Wainwright M; Widner H; Johansson A
    Acta Neurol Scand; 2012 Dec; 126(6):e29-33. PubMed ID: 22690905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinemet CR in Parkinson's disease.
    Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R
    Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson's disease in Sweden: an exploratory study.
    Kristiansen IS; Bingefors K; Nyholm D; Isacson D
    Appl Health Econ Health Policy; 2009; 7(3):167-80. PubMed ID: 19799471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 20. [Advanced course of Parkinson disease. Little improved motion with continuous intestinal levodopa administration].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):245-6. PubMed ID: 16038123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.